#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Effect of antidiabetic treatment on incidence of stroke in patients with type 2. diabetes

Czech version

Authors: Ivan Tkáč
Authors‘ workplace: IV. interná klinika UPJŠ LF a UN LP Košice, Excelentný tím pre výskum aterosklerózy (EXTASY)
Published in: Forum Diab 2021; 10(Supplementum 1): 46-52
Category:

Overview

Stroke occurs more than twice as often in patients with diabetes compared to the non-diabetic population of the same age. Diabetes mellitus is a strong risk factor, especially for ischemic strokes, which account for approximately 90% of all strokes. The incidence of stroke is favourably influenced by LDL-cholesterol-lowering therapy as well as anti­hypertensive therapy, especially renin-angiotensin system inhibitors. Studies which aimed at achieving the best possible glycemic control have failed to demonstrate the benefit of better diabetic control in preventing the development of stroke. Among the different groups of newer antidiabetic drugs, the benefit of DPP-4 inhibitors, SGLT2 inhibitors, or insulin analogues in preventing the development of stroke has not been demonstrated. A meta-analysis of studies with glitazones showed a beneficial effect of this group of drugs in preventing the development of stroke, but their serious side effects have led to their limited use in the last decade. GLP-1 receptor agonists (GLP1-RA) as adjunctive therapy in trials with semaglutide and dulaglutide have demonstrated the ability to reduce the incidence of stroke significantly compared with placebo. Similarly, a meta-analysis of eight trials published to date with GLP1-RA showed a significant 17% reduction in the incidence of stroke. The protective effect of GLP1-RA against stroke is mediated by multiple mechanisms. GLP1-RA exert an antiatherogenic effect in all arterial beds mediated by the interactions with the process of atherogenesis at the level of endothelium, media, platelet aggregation, and other tissues. In addition, GLP1-RA also appear to have a protective effect directly in the brain, which, in addition to a preventive effect against the development of stroke, is manifested by a reduction in the ischemic loci with GLP1-RA treatment.

Keywords:

atherosclerosis- GLP-1 receptor agonists – preventive effect – stroke

Sources
  1. Sarwar N, Gao P, Kondapally Seshasai SR et al. [Emerging Risk Factors Collaboration]. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733): 2215–2222. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60484–9>.
  2. An SJ, Kim TJ, Yoon B-W. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: An update. J Stroke 2017; 19(1): 3–10. Dostupné z DOI: <http://dx.doi.org/10.5853/jos.2016.00864>.
  3. Kleindorfer DO, Towfighi A, Chaturvedi S et al. 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52(7): e364-e467. Dostupné z DOI: <http://dx.doi.org/10.1161/STR.0000000000000375>.
  4. Rawshani Ad, Rawshani Ar, Franzén S et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379(7): 633–644. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1800256>.
  5. Emdin CA, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.
  6. [Heart Outcomes Prevention Evaluation (HOPE) Study Investigators]. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 358(9200): 253–259.
  7. Kearney PM, L Blackwell L, Collins R et al. [Cholesterol Treatment Trialists‘ (CTT) Collaborators]. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–125. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60104-X>.
  8. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
  9. Schwartz GG, Steg PG, Szarek M et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379(22): 2097–2107. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1801174>.
  10. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52(11): 2288–2298. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–009–1470–0>. Erratum in Diabetologia 2009;52(1):2470. Control Group [added].
  11. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67528–9>.
  12. Philip D, Home PD, Stuart J et al. [RECORD Study Team]. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681: 2125–2135. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60953–3>.
  13. Vaccaro O, Masulli M, Nicolucci A et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5(11): 887–897. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30317–0>.
  14. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1317–1326. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1307684>.
  15. White WB, Cannon CC, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327–1335. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1305889>.
  16. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232–242. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501352>.
  17. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomised clinical trial. JAMA 2019; 321(1): 69–79. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2018.18269>.
  18. Rosenstock J, Kahn SE, Johansen OE et al. Effect of linagliptin vs glimepiride on major cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA randomized clinical trial. JAMA 2019; 322(12): 1155–1166. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2019.13772>.
  19. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247–2257. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1509225>.
  20. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
  21. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.
  22. Holman RR, Bethel MA, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228–1239. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1612917>.
  23. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32261-X>.
  24. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné
    z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.
  25. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381(9): 841–851. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1901118>.
  26. Gerstein HC, Sattar N, Rosenstock J et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021; 385(10): 896–907. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2108269>.
  27. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
  28. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
  29. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.
  30. Cannon CP, Pretley R, Dogogo-Jack S et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383(15): 1425–1435. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2004967>.
  31. C Gerstein HC, Bosch J, Dagenais GR et al. [ORIGIN Trial Investigators]. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1203858>.
  32. Marso SP, McGuire DK, Zinman B et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017; 377(8): 723–732. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615692>.
  33. Drucker DJ. Mechanism of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27(4): 740–756. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2018.03.001>.
  34. Maskery MP, Holscher C, Jones SP et al. Glucagon like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. J Cereb Blood Flow Metab 2021; 41(1): 14–30. Dostupné z DOI: <http://dx.doi.org/10.1177/0271678X20952011>.
  35. Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.
Labels
Diabetology Endocrinology Internal medicine
Súčasné možnosti prevencie aterosklerózy pri diabete
Antidiabetic treatment in prevention of atherosclerosis: last decade
Hypolipidemic treatment in the prevention of atherosclerosis in diabetic patients
Antihypertensive treatment in the prevention of atherosclerosis in diabetic patients
Antiplatelet therapy for prevention of atherosclerosis in patients with diabetes
Antidiabetic treatment in prevention of atherosclerosis: first half-century
Limitation and possible additive value of real world evidence in comparison with randomized clinical trials
Facts to remember: What is based on the evidence in atherosclerosis prevention in type 2 diabetes?
Article was published in

Forum Diabetologicum

Issue Supplementum 1
2021 Issue Supplementum 1
Download issue PDF
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#